Cara Therapeutics, Inc. (NASDAQ:CARA) Short Interest Update

Cara Therapeutics, Inc. (NASDAQ:CARA) was the recipient of a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 576,700 shares, a decrease of 54.2% from the November 15th total of 1,260,000 shares. Based on an average trading volume of 541,600 shares, the short-interest ratio is currently 1.1 days. Approximately 1.3% of the shares of the stock are sold short.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on Cara Therapeutics in a research report on Saturday, December 7th. They set a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating and five have issued a hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $2.32.

Hedge Funds Weigh In On Cara Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in CARA. XTX Topco Ltd acquired a new stake in Cara Therapeutics during the 3rd quarter valued at $29,000. FMR LLC grew its stake in shares of Cara Therapeutics by 18.5% during the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 32,789 shares in the last quarter. Finally, Disciplined Growth Investors Inc. MN grew its stake in shares of Cara Therapeutics by 6.6% during the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock valued at $499,000 after acquiring an additional 120,660 shares in the last quarter. Institutional investors and hedge funds own 44.66% of the company’s stock.

Cara Therapeutics Price Performance

CARA stock traded up $0.00 during midday trading on Friday, reaching $0.26. 1,006,388 shares of the company’s stock traded hands, compared to its average volume of 638,491. Cara Therapeutics has a fifty-two week low of $0.24 and a fifty-two week high of $1.31. The business has a 50-day moving average price of $0.29 and a two-hundred day moving average price of $0.34. The company has a market capitalization of $14.37 million, a P/E ratio of -0.15 and a beta of 0.64.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.